BioLineRx (BLRX) Consolidated Net Income (2011 - 2025)

BioLineRx's Consolidated Net Income history runs 14 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• On a quarterly basis, Consolidated Net Income rose 29.84% year-over-year to -$2.2 million in Q4 2025; TTM through Dec 2025 was -$2.0 million, a 78.03% increase from a year earlier, with the FY2025 full-year figure at -$2.0 million, up 78.03% from the prior year.
• Consolidated Net Income fell to -$2.2 million in Q4 2025 per BLRX's latest filing, from -$977000.0 in the prior quarter.
• Across five years, Consolidated Net Income topped out at $5.1 million in Q1 2025 and bottomed at -$23.1 million in Q4 2023.
• The 5-year median for Consolidated Net Income is -$6.0 million (2021), against an average of -$5.8 million.
• Biggest YoY gain for Consolidated Net Income was 836.64% in 2025; the steepest drop was 533.92% in 2025.
• Year by year, Consolidated Net Income stood at -$8.1 million in 2021, then sank by 30.21% to -$10.6 million in 2022, then slumped by 117.97% to -$23.1 million in 2023, then surged by 86.18% to -$3.2 million in 2024, then climbed by 29.84% to -$2.2 million in 2025.
• Per Business Quant, the three latest BLRX Consolidated Net Income figures stand at -$2.2 million (Q4 2025), -$977000.0 (Q3 2025), and -$3.9 million (Q2 2025).